JP2021508707A5 - - Google Patents

Download PDF

Info

Publication number
JP2021508707A5
JP2021508707A5 JP2020536100A JP2020536100A JP2021508707A5 JP 2021508707 A5 JP2021508707 A5 JP 2021508707A5 JP 2020536100 A JP2020536100 A JP 2020536100A JP 2020536100 A JP2020536100 A JP 2020536100A JP 2021508707 A5 JP2021508707 A5 JP 2021508707A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020536100A
Other languages
English (en)
Japanese (ja)
Other versions
JP7383617B2 (ja
JP2021508707A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2018/124925 external-priority patent/WO2019129211A1/en
Publication of JP2021508707A publication Critical patent/JP2021508707A/ja
Publication of JP2021508707A5 publication Critical patent/JP2021508707A5/ja
Application granted granted Critical
Publication of JP7383617B2 publication Critical patent/JP7383617B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020536100A 2017-12-28 2018-12-28 Pd-l1に対する抗体及びそのバリアント Active JP7383617B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/119505 2017-12-28
CN2017119505 2017-12-28
PCT/CN2018/124925 WO2019129211A1 (en) 2017-12-28 2018-12-28 Antibodies and variants thereof against pd-l1

Publications (3)

Publication Number Publication Date
JP2021508707A JP2021508707A (ja) 2021-03-11
JP2021508707A5 true JP2021508707A5 (enExample) 2021-07-26
JP7383617B2 JP7383617B2 (ja) 2023-11-20

Family

ID=67066642

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020536100A Active JP7383617B2 (ja) 2017-12-28 2018-12-28 Pd-l1に対する抗体及びそのバリアント

Country Status (11)

Country Link
US (1) US12168688B2 (enExample)
EP (1) EP3732203A4 (enExample)
JP (1) JP7383617B2 (enExample)
KR (1) KR102845020B1 (enExample)
CN (1) CN111542543B (enExample)
AU (1) AU2018396964C1 (enExample)
CA (1) CA3078849A1 (enExample)
IL (1) IL275577A (enExample)
SG (1) SG11202005273XA (enExample)
TW (1) TW201930350A (enExample)
WO (1) WO2019129211A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7383617B2 (ja) 2017-12-28 2023-11-20 ナンジン レジェンド バイオテック カンパニー,リミテッド Pd-l1に対する抗体及びそのバリアント
TW202020159A (zh) * 2018-11-16 2020-06-01 大陸商南京金斯瑞生物科技有限公司 人源化抗人pd-l1單克隆抗體及其製備方法和用途
US20220220204A1 (en) * 2019-06-12 2022-07-14 Nanjing GenScript Biotech Co., Ltd. Anti-pd-l1/anti-lag-3 multiple antigen binding proteins and methods of use thereof
WO2021036929A1 (en) * 2019-08-23 2021-03-04 Wuxi Biologics (Shanghai) Co., Ltd. Humanized antibodies against pd-l1
BR112021016512A2 (pt) 2019-08-29 2022-03-15 Remegen Co Ltd Anticorpo anti pd-l1 e uso do mesmo
US11877018B2 (en) 2019-11-15 2024-01-16 Korea Advanced Institute Of Science And Technology Live video ingest system and method
US20230093512A1 (en) * 2020-02-18 2023-03-23 Nanjing GenScript Biotech Co., Ltd. Fusion proteins and uses thereof
US20230303699A1 (en) * 2020-08-04 2023-09-28 Exelixis, Inc. Pd-l1 binding agents and uses thereof
CN115521378B (zh) * 2021-07-23 2023-12-22 南京吉盛澳玛生物医药有限公司 Pd-l1抗体及其用途
US20250035633A1 (en) * 2021-10-08 2025-01-30 Arbele Limited Compositions and methods for detecting cadherin-17 protein
KR102534281B1 (ko) * 2022-09-02 2023-05-30 한국생명공학연구원 신규한 항-pd-l1 키메릭 항원 수용체 및 이를 발현하는 면역세포
EP4658310A1 (en) 2023-01-30 2025-12-10 Kymab Limited Antibodies

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル,インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ATE531812T1 (de) 1997-12-05 2011-11-15 Scripps Research Inst Humanisierung von nager-antikörpern
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1068241T3 (da) 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
US7504256B1 (en) 1999-10-19 2009-03-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
EP1240319A1 (en) 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
MXPA03002974A (es) 2000-10-06 2004-05-05 Kyowa Hakko Kogyo Kk Celulas que producen composiciones de anticuerpo.
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
KR100857943B1 (ko) 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
CA2838062C (en) 2001-08-03 2015-12-22 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
NZ532526A (en) 2001-10-25 2007-01-26 Genentech Inc Compositions comprising a glycoprotein having a Fc region
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
JP4628679B2 (ja) 2002-04-09 2011-02-09 協和発酵キリン株式会社 Gdp−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
AU2003236019A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
MXPA04009924A (es) 2002-04-09 2005-07-01 Kyowa Hakko Kogyo Kk Celulas de genoma modificado.
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
WO2003084569A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Drug containing antibody composition
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004042072A2 (en) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
AR042485A1 (es) 2002-12-16 2005-06-22 Genentech Inc Anticuerpo humanizado que se une al cd20 humano
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
AU2004280065A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
TR201809892T4 (tr) 2003-11-05 2018-07-23 Roche Glycart Ag Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller.
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
CA2885854C (en) 2004-04-13 2017-02-21 F. Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
US20090307787A1 (en) 2006-01-25 2009-12-10 Franklin Gerardus Grosveld Generation of heavy-chain only antibodies in transgenic animals
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
CN101104640A (zh) 2006-07-10 2008-01-16 苏州大学 抗人pd-l1单克隆抗体制备及应用
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
PT2215119E (pt) * 2007-11-13 2013-02-11 Boehringer Ingelheim Int Anticorpos monoclonais que se ligam a hgm-csf e composições médicas que os compreendem
CA2706200A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Immunoglobulin constructs comprising multiple single variable domains and an fc portion
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
MX2011003195A (es) * 2008-09-26 2011-08-12 Dana Farber Cancer Inst Inc Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
US8217149B2 (en) * 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
SMT201900251T1 (it) 2009-12-10 2019-07-11 Regeneron Pharma Topi che producono anticorpi della catena pesante
LT2785375T (lt) * 2011-11-28 2020-11-10 Merck Patent Gmbh Anti-pd-l1 antikūnai ir jų panaudojimas
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗pd-l1之人類抗體
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
JP6526189B2 (ja) * 2014-07-03 2019-06-05 ベイジーン リミテッド 抗pd−l1抗体並びにその治療及び診断のための使用
RU2722212C9 (ru) 2014-08-05 2020-07-23 СиБи ТЕРЕПЬЮТИКС, ИНК. Анти-pd-l1 антитела
CN105777906B (zh) 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
WO2017020291A1 (en) * 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
CA3004804A1 (en) * 2015-11-17 2017-05-26 Jiangsu Hengrui Medicine Co., Ltd. Pd-l1 antibody, antigen-binding fragment thereof and medical application thereof
CA3132021C (en) * 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
HK1247214B (zh) * 2016-03-04 2019-07-19 四川科伦博泰生物医药股份有限公司 一种pdl-1抗体、其药物组合物及其用途
WO2017161976A1 (en) 2016-03-23 2017-09-28 Mabspace Biosciences (Suzhou) Co., Ltd Novel anti-pd-l1 antibodies
JP7116685B2 (ja) * 2016-04-15 2022-08-10 エイチ. ルンドベック アー/エス ヒト化抗pacap抗体及びそれらの使用
AR108377A1 (es) * 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
CN105968200B (zh) 2016-05-20 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-l1人源化单克隆抗体及其应用
SG11201811003PA (en) 2016-06-13 2019-01-30 I Mab Anti-pd-l1 antibodies and uses thereof
CN107488229B (zh) * 2016-06-13 2020-11-17 天境生物科技(上海)有限公司 Pd-l1抗体及其用途
WO2017218707A2 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
CN108239149B (zh) * 2016-12-25 2021-03-05 南京传奇生物科技有限公司 高亲和力、高特异性、多抗原识别表位的具有更高功能性的抗人pd-l1抗体
US11285207B2 (en) * 2017-04-05 2022-03-29 Hoffmann-La Roche Inc. Bispecific antibodies specifically binding to PD1 and LAG3
JP7383617B2 (ja) 2017-12-28 2023-11-20 ナンジン レジェンド バイオテック カンパニー,リミテッド Pd-l1に対する抗体及びそのバリアント

Similar Documents

Publication Publication Date Title
JP2021508707A5 (enExample)
JP2021503455A5 (enExample)
JP2019524693A5 (enExample)
FI3625259T3 (fi) Anti-sirp-alfa vasta-aineet
JP2017535257A5 (enExample)
JP2020515247A5 (enExample)
JP2019533719A5 (enExample)
JP2017504578A5 (enExample)
JP2014522850A5 (enExample)
JPWO2019137548A5 (enExample)
JP2018093875A5 (enExample)
JP2018536632A5 (ja) B7‐h3に特異的に結合する分子及びpd‐1に特異的に結合する分子
JP2012519492A5 (enExample)
FI3941946T3 (fi) Klaudiini-6-vasta-aineita ja klaudiini-6-vasta-ainelääkekonjugaatteja
JP2015509960A5 (enExample)
JP2020502233A5 (enExample)
JP2020515277A5 (enExample)
WO2019195313A1 (en) Anti-vegf antagonist and pedf agonist constructs and uses thereof
JP2024504124A (ja) 新規の抗グレムリン1抗体
JP2024001073A5 (enExample)
JP2020522488A5 (enExample)
FI3830132T3 (fi) Humanisoituja vasta-aineita psma:ta vastaan
JP2020513759A5 (enExample)
FI3452515T3 (fi) HER-2 sitoutuvia vasta-aineita
JP2016529213A5 (enExample)